These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 15458462)

  • 1. Effect of spironolactone on K(+) homeostasis and ENaC expression in lymphocytes from chronic hemodialysis patients.
    Michea L; Vukusich A; González M; Zehnder C; Marusic ET
    Kidney Int; 2004 Oct; 66(4):1647-53. PubMed ID: 15458462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients.
    Gross E; Rothstein M; Dombek S; Juknis HI
    Am J Kidney Dis; 2005 Jul; 46(1):94-101. PubMed ID: 15983962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of low-dose spironolactone administration in chronic haemodialysis patients.
    Saudan P; Mach F; Perneger T; Schnetzler B; Stoermann C; Fumeaux Z; Rossier M; Martin PY
    Nephrol Dial Transplant; 2003 Nov; 18(11):2359-63. PubMed ID: 14551366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term low-dose spironolactone therapy is safe in oligoanuric hemodialysis patients.
    Matsumoto Y; Kageyama S; Yakushigawa T; Arihara K; Sugiyama T; Mori Y; Sugiyama H; Ohmura H; Shio N
    Cardiology; 2009; 114(1):32-8. PubMed ID: 19342857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
    Khosla N; Kalaitzidis R; Bakris GL
    Am J Nephrol; 2009; 30(5):418-24. PubMed ID: 19738369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is spironolactone safe for dialysis patients?
    Hussain S; Dreyfus DE; Marcus RJ; Biederman RW; McGill RL
    Nephrol Dial Transplant; 2003 Nov; 18(11):2364-8. PubMed ID: 14551367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium transporter abundance profiling in kidney: effect of spironolactone.
    Nielsen J; Kwon TH; Masilamani S; Beutler K; Hager H; Nielsen S; Knepper MA
    Am J Physiol Renal Physiol; 2002 Nov; 283(5):F923-33. PubMed ID: 12372767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (Pro)Renin receptor regulates potassium homeostasis through a local mechanism.
    Xu C; Lu A; Wang H; Fang H; Zhou L; Sun P; Yang T
    Am J Physiol Renal Physiol; 2017 Sep; 313(3):F641-F656. PubMed ID: 27440776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin and mineralocorticoids influence on extrarenal potassium metabolism in chronic hemodialysis patients.
    Vlassopoulos D; Sonikian M; Dardioti V; Pani I; Hadjilouka-Mantaka A; Hadjiconstantinou V
    Ren Fail; 2001 Nov; 23(6):833-42. PubMed ID: 11777323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood pressure responses to small doses of amiloride and spironolactone in normotensive subjects.
    Pratt JH; Eckert GJ; Newman S; Ambrosius WT
    Hypertension; 2001 Nov; 38(5):1124-9. PubMed ID: 11711509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients.
    Vukusich A; Kunstmann S; Varela C; Gainza D; Bravo S; Sepulveda D; Cavada G; Michea L; Marusic ET
    Clin J Am Soc Nephrol; 2010 Aug; 5(8):1380-7. PubMed ID: 20522535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lithium-induced NDI in rats is associated with loss of alpha-ENaC regulation by aldosterone in CCD.
    Nielsen J; Kwon TH; Frøkiaer J; Knepper MA; Nielsen S
    Am J Physiol Renal Physiol; 2006 May; 290(5):F1222-33. PubMed ID: 16332930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease.
    Bianchi S; Bigazzi R; Campese VM
    Kidney Int; 2006 Dec; 70(12):2116-23. PubMed ID: 17035949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial.
    Charytan DM; Himmelfarb J; Ikizler TA; Raj DS; Hsu JY; Landis JR; Anderson AH; Hung AM; Mehrotra R; Sharma S; Weiner DE; Williams M; DiCarli M; Skali H; Kimmel PL; Kliger AS; Dember LM;
    Kidney Int; 2019 Apr; 95(4):973-982. PubMed ID: 30473139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial.
    Edwards NC; Steeds RP; Stewart PM; Ferro CJ; Townend JN
    J Am Coll Cardiol; 2009 Aug; 54(6):505-12. PubMed ID: 19643310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Safety of Eplerenone in Hemodialysis Patients: A Noninferiority Randomized Controlled Trial.
    Walsh M; Manns B; Garg AX; Bueti J; Rabbat C; Smyth A; Tyrwhitt J; Bosch J; Gao P; Devereaux PJ; Wald R
    Clin J Am Soc Nephrol; 2015 Sep; 10(9):1602-8. PubMed ID: 26138259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients.
    Matsumoto Y; Mori Y; Kageyama S; Arihara K; Sugiyama T; Ohmura H; Yakushigawa T; Sugiyama H; Shimada Y; Nojima Y; Shio N
    J Am Coll Cardiol; 2014 Feb; 63(6):528-36. PubMed ID: 24184249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of spironolactone in hypertensive patients on regular haemodialysis and after renal allotransplantation.
    Papadimitriou M; Vyzantiadis A; Milionis A; Memmos D; Metaxas P
    Life Support Syst; 1983; 1(3):197-205. PubMed ID: 6433115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale and design of the Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease Study (MiREnDa).
    Hammer F; Krane V; Störk S; Röser C; Hofmann K; Pollak N; Allolio B; Wanner C
    Nephrol Dial Transplant; 2014 Feb; 29(2):400-5. PubMed ID: 24166468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mice heterozygous for beta-ENaC deletion have defective potassium excretion.
    Cao XR; Shi PP; Sigmund RD; Husted RF; Sigmund CD; Williamson RA; Stokes JB; Yang B
    Am J Physiol Renal Physiol; 2006 Jul; 291(1):F107-15. PubMed ID: 16571596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.